Update released from NHS England regarding use of adjuvanted trivalent flu vaccine for 2018-19 flu season . The adjuvanted trivalent inactivated flu vaccine (Fluad®: Seqirus) was licensed late in 2017 and is available for use in the 2018-19 season. Based on available evidence, JCVI concluded at its October 2017 meeting that adjuvanted trivalent flu vaccine is more effective and highly cost effective in those aged over 65 years and above compared with the nonadjuvanted or ‘normal’ influenza vaccines currently used in the UK for this age-group. The JCVI has accordingly advised that the use of the adjuvanted trivalent flu vaccine should be a priority for those aged 75 years and over, given that the non-adjuvanted inactivated vaccine has showed no significant effectiveness in this group over recent seasons, and the adjuvanted trivalent flu vaccine is therefore currently considered to be the only licensed cost-effective option for this group.
More information regarding the update & other hints & tips for ordering flu vaccines: Click Here
Influenza chapter of the ‘Green Book’ can be found at: Click Here